Quality of life and its association with direct medical costs for COPD in urban China

Health and Quality of Life Outcomes

Biao Xu²  Chaowei Fu²  Yue Chen¹  Qi Zhao²  Minmin Wu² 

[1] Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada;School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai 200032, China

关键词: Medical cost;    A cross-sectional study;    Quality of life;    Chronic obstructive pulmonary disease;   

Others  :  1209249
DOI  :  10.1186/s12955-015-0241-5

 received in 2014-10-08, accepted in 2015-04-02,  发布年份 2015

【 摘 要 】

Background

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide. Few studies have focused on the quality of life (QoL) associated medical costs for COPD in China.

Methods

A cross-sectional survey of 678 COPD patients was conducted in four major cities (Beijing, Shanghai, Guangzhou and Chengdu), China, in 2011. Data on socio-demographic information, health conditions and medical costs were collected through a face-to-face interview combined with medical record searching. The EuroQol (EQ-5D) health questionnaire was applied to assess the QoL of COPD patients.

Results

Among 678 patients with COPD, nearly 40% had difficulties in mobility, usual activities and pain/discomfort, one third had various degrees of anxiety/depression, and one fifth had difficulties in self-care. The COPD patients had a median utility score of 0.768 and a median visual analog scale score of 70. The degree of difficulties in any dimensions significantly increased, and utility and health scores decreased with severity of the disease. Age, gender and disease severity were significantly associated with the quality of life after taking other covariates into consideration. Poorer QoL was a significant indicator of higher direct medical costs for COPD patients.

Conclusion

Impaired quality of life was significantly linked to increased medical costs for COPD patients and could be an important measure for policy- and decision-making in COPD care.

【 授权许可】

   
2015 Wu et al.; licensee BioMed Central.

【 参考文献 】

• [1]WHO. The top 10 causes of death. Available: http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed April 11, 2015.
• [2]Decramer M, Sibille Y, Bush A, Carlsen K-H, Rabe KF, Clancye L et al.. The European Union conference on chronic respiratory disease: purpose and conclusions. Eur Respir J. 2011; 37(4):738-742.
• [3]Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S et al.. Prevalence of Chronic Obstructive Pulmonary Disease in China: A Large, Population-based Survey. Am J Respir Crit Care Med. 2007; 176(8):753-760.
• [4]Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013; 5:235-45.
• [5]Haave E, Hyland ME, Skumlien S. The relation between measures of health status and quality of life in COPD. Chron Respir Dis. 2006; 3:195-199.
• [6]Weinstein MC, Siegel JE, Gold MR, Kamlet MS. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996; 276:1253-1258.
• [7]Ramli A, Leonard J, Harun R. Preliminary evidence on the Feldenkrais Method as an alternative therapy for patients with chronic obstructive pulmonary disease. Focus on Alternative & Complementary Therapies an Evidence-Based Approach. 2013; 18(3):126-132.
• [8]Blankenburg T, Guettel A, Busch C, Schuette W. Six-minute walk distance and dyspnoea scores to assess the course of COPD exacerbation in elderly patients. Clinical Respiratory Journal. 2013; 7(3):261-267.
• [9]Shino Michael Y, Lynch JP, Saggar R, Abtin F, Belperio JA, Saggar R. Pulmonary Hypertension Complicating Interstitial Lung Disease and COPD. Seminars in Respiratory & Critical Care Medicine. 2013; 34(5):600-619.
• [10]Yorgancioglu A, Havlucu Y, Celik P, Dinc G, Saka A. Relation between quality of life and morbidity and mortality in COPD patients: Two-year follow-up study. COPD. 2010; 7(4):248-53.
• [11]Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary diseasepatients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012; 7:757-64.
• [12]Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014; 9:65-73.
• [13]Thayer RE, Newman JR, McClain TM. Self-regulation of mood: strategies for changing a bad mood, raising energy, and reducing tension. J Pers Soc Psychol. 1994; 67(5):910-25.
• [14]Lemmens KM, Nieboer AP, Huijsman R. Designing patient related interventions in COPD care: empirical test of a theoretical model. Patient Educ Couns. 2008; 72:223-31.
• [15]Ninot G, Moullec G, Picot MC, Jaussent A, Hayot M, Desplan M et al.. Cost-saving effect of supervised exercise associated to COPD self-management education program. Respir Med. 2011; 105:377-85.
• [16]Collaboration P-T. Optimizing chronic disease management mega-analysis: economic evaluation. Ont Health Technol Assess Ser. 2013; 13:1-148.
• [17]Susan G, Kathleen M. Fox and for the SHIELD Study Group: Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study. Health and Qulity of Life Outcoms. 2012; 10:99-106. BioMed Central Full Text
• [18]COPD Group of Chinese Thoracic Society. The guideline for the diagnosis and treatment of COPD (updated in 2007). Ji Xu Yi Xue Jiao Yu, 2009;21(2):21-42.
• [19]Macran S, Weatherly H, Kind P. Measuring population health: a comparison of three generic health status measures. Med Care. 2003; 41:218-31.
• [20]Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford University Press, New York; 1996.
• [21]Global Strategy for Diagnosis, Management, and Prevention of COPD. Available: http://www.goldcopd.com/guidelines-global-strategy-for-diagnosis-management.html. Accessed April 11, 2015.
• [22]Suchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T et al.. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002; 11(4):341-353.
• [23]Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics. 2007; 25(5):365-84.
• [24]Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005; 43(7):736-49.
• [25]Osman LM, Ayres JG, Garden C, Reglitz K, Lyon J, Douglas JG. Home warmth and health status of COPD patients. Eur J Public Health. 2008; 18(4):399-405.
• [26]Ståhl E1, Lindberg A, Jansson SA, Rönmark E, Svensson K, Andersson F et al.. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005; 3:56. BioMed Central Full Text
• [27]Pickard AS, Yang Y, Lee TA. Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2011; 9:26. BioMed Central Full Text
• [28]Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006; 130(4):1117-28.
• [29]Kim SH, Oh YM, Jo MW. Health-related quality of life in chronic obstructive pulmonary disease patients in Korea. Health Qual Life Outcomes. 2014; 12:57. BioMed Central Full Text
• [30]Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res. 1999; 8(1–2):45-54.
• [31]Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000; 38(6):583-637.
• [32]Pickard AS, Wilke C, Jung E, Patel S, Stavem K, Lee TA. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respir Med. 2008; 102(4):519-36.